Simultaneous coexpression of memory-related and effector-related genes by individual human CD8 T cells depends on antigen specificity and differentiation. by Gupta, B. et al.
  
Serveur Académique Lausannois SERVAL serval.unil.ch 
Author Manuscript 
Faculty of Biology and Medicine Publication 
This paper has been peer-reviewed but dos not include the final publisher 
proof-corrections or journal pagination. 
Published in final edited form as:  
 
In the absence of a copyright statement, users should assume that standard copyright protection applies, unless the article contains 
an explicit statement to the contrary. In case of doubt, contact the journal publisher to verify the copyright status of an article. 
 
Title: Simultaneous coexpression of memory-related and effector-
related genes by individual human CD8 T cells depends on antigen 
specificity and differentiation. 
Authors: Gupta B, Iancu EM, Gannon PO, Wieckowski S, Baitsch L, 
Speiser DE, Rufer N 
Journal: Journal of immunotherapy (Hagerstown, Md. : 1997) 
Year: 2012 Jul 
Volume: 35 
Issue: 6 
Pages: 488-501 
DOI: 10.1097/CJI.0b013e31826183a7 
 
Simultaneous co-expression of memory- and effector-related genes by individual 
human CD8 T cells depends on antigen specificity and differentiation 
Bhawna Gupta1,*, Emanuela M. Iancu1,*, Philippe O. Gannon1,*, Sébastien 
Wieckowski1, Lukas Baitsch2, Daniel E. Speiser2 and Nathalie Rufer1,2  
1Department of Research, Lausanne University Hospital, Lausanne, Switzerland 
2Ludwig Center for Cancer Research, University of Lausanne, Lausanne, Switzerland 
* These authors contributed equally to this work
Address correspondence to: Nathalie Rufer, PhD, Department of Research, 
Lausanne University Hospital, c/o HO, niv 5, Avenue Pierre-Decker 4, CH-1011 
Lausanne, Switzerland; Nathalie.Rufer@unil.ch  
Running title: Single T cell gene co-expression profiling 
Keywords: human, melanoma, vaccination, EBV, CMV, CD8 T cells, single-cell, 
TCR clonotype, cell differentiation, memory, homing, effector, gene expression 
Abbreviations: IFA, Incomplete Freund’s Adjuvant; EBV, Epstein-Barr virus; 
CMV, Cytomegalovirus 
Author contributions: B.G., E.M.I., P.O.G., D.E.S., and N.R. designed research. 
B.G., E.M.I., P.O.G., S.W., L.B. and N.R. performed research and analyzed data. 
B.G., P.O.G., D.E.S., and N.R. wrote the manuscript. 
1 
  Version 05.05.2012    
ABSTRACT 
Phenotypic and functional cell properties are usually analyzed at the level of defined 
cell populations but not single cells. Yet, large differences between individual cells 
may have important functional consequences. It is likely that T cell mediated 
immunity depends on the polyfunctionality of individual T cells, rather than the sum 
of functions of responding T cell subpopulations. We performed highly sensitive 
single-cell gene expression profiling, allowing the direct ex vivo characterization of 
individual virus- and tumor-specific T cells from healthy donors and melanoma 
patients. We have previously shown that vaccination with the natural tumor peptide 
Melan-AMART-126-35 induced T cells with superior effector functions as compared to 
vaccination with the analog peptide optimized for enhanced HLA-A*0201 binding. 
Here we found that natural peptide vaccination induced tumor-reactive CD8pos T cells 
with frequent co-expression of both memory/homing-associated genes (CD27, IL7R, 
EOMES, CXCR3 and CCR5) and effector-related genes (IFNG, KLRD1, PRF1, and 
GZMB), comparable to protective EBV- and CMV-specific T cells. In contrast, 
memory/homing- and effector-associated genes were less frequently co-expressed 
after vaccination with the analog peptide. Remarkably, these findings reveal a 
previously unknown level of gene expression diversity among vaccine- and virus-
specific T cells with the simultaneous co-expression of multiple memory/homing- 
and effector-related genes by the same cell. Such broad functional gene expression 
signatures within antigen-specific T cells may be critical for mounting efficient 
responses to pathogens or tumors. In summary, direct ex vivo high-resolution 
molecular characterization of individual T cells provides key insights into the 
processes shaping the functional properties of tumor- and virus-specific T cells.  
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INTRODUCTION 
Analysis of the generation, function and long-term persistence of effector and 
memory T lymphocytes has been of fundamental importance to our understanding of 
protective immunity and to improve therapeutic vaccine strategies. Following TCR 
triggering, naive T cell precursors differentiate into antigen-experienced CD8pos T 
lymphocytes, forming highly heterogeneous memory- and effector-like 
subpopulations based on their phenotype, function and anatomic location.1-3 During T 
cell differentiation, stochastic events involve a set of modifications of multiple gene 
expressions inducing drastic changes in the cell and thus sustaining variability among 
the antigen-primed subpopulations. A powerful approach to explore the biological 
basis underlying differentiation of memory- and effector-like T cell subsets relies on 
molecular gene signature analyses using DNA microarrays. For instance, gene 
expression profiling led to the identification of memory- and effector-associated gene 
expression markers defining distinct functional properties of memory progenitor and 
terminal effector CD8pos T cells,4-6 and provided new insights in the progressive 
generation of those subsets during acute viral infection.7,8 Genome-wide analysis 
further revealed a gene expression program diversion between CD4pos and CD8pos T 
cells at early stages of differentiation, contrasting with the similar molecular profiles 
found as cells reach later differentiation stages.9 Moreover, functional cell exhaustion 
was associated with numerous molecular alterations in virus-specific T cells from 
chronic infections,10 as well as in tumor-specific T cells from melanoma patient 
metastases.11 
A major limitation of gene microarrays lies in the fact that the resulting data only 
determine the average gene expression within a given cell population, thus masking 
the cell-to-cell variations potentially associated with different cellular functions or 
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outcomes.12 In order to obtain accurate gene expression patterns among quasi-
homogenous cell populations, there arises a need for single-cell analysis providing 
the highest resolution. In recent years, major efforts have been made to develop 
precise measurement of single-cell gene expression states in various biological 
models.13-16 In particular, Peixoto, Rocha and colleagues17 described a RT-PCR 
approach to quantify the expression of 20 different genes simultaneously from a 
single antigen-specific expanded T cell. Despite studying a relative homogeneous cell 
population, they demonstrated significant cell-to-cell heterogeneity in terms of gene 
co-expression. Accumulating data indicate that a seemingly homogeneous population 
does not represent any one individual cell, but rather reveal unique patterns of gene 
expression within individual cells. 
For an in-depth monitoring of antigen-specific T cell responses, a key endpoint is to 
relate the expression of specific gene patterns to a distinct cellular phenotype. As 
such, single-cell gene expression profiling can provide a tight correlation between 
specific cell surface markers and CD8pos T cell functional properties.18 Specifically it 
was shown, that each memory- and effector-like CD8pos T cell subset displayed a 
unique pattern of gene expression, with the progressive up-regulation of multiple 
effector mediators by the same cell along cell differentiation.18 Cellular immune 
responses generated following therapeutic vaccines have also been described as 
highly diverse in terms of phenotype and functionality.19 Recently Flatz and 
colleagues identified previously unrecognized subsets of CD8pos T cells based upon 
analysis of gene-expression patterns within single cells and showed that they were 
differentially induced by different vaccines.20 These studies emphasize the strong 
need to delineate the qualitative attributes of vaccine-induced CD8pos T cell 
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responses, not only at the phenotypic/functional levels but as well by defining the 
genetic signatures of single cells. 
In the present study, we investigated the direct ex vivo properties of individual virus- 
and tumor-specific CD8pos T cells from healthy donors and from melanoma patients. 
The latter had been vaccinated with low dose of either the natural or the analog 
modified Melan-AMART-126-35 peptide, mixed with CpG 7909 and Incomplete 
Freund’s adjuvant (IFA).21 Previously, we have shown that natural peptide induced T 
cells, which had enhanced overall functionality and increased capacity to recognize 
tumor cells compared to T cells stimulated by the analog peptide.21 Recently, we 
applied a modified RT-PCR protocol for direct ex vivo single T cell analysis,22,23 and 
found that non-dominant CD8pos T cell clonotypes showed similar activation and 
differentiation as their dominant counterparts following natural peptide vaccination.24 
Here we extended the highly sensitive and specific single-cell approach to the 
analysis of multiple memory/homing- (CD27, IL7R, EOMES, CXCR3, and CCR5) 
and effector- (IFNG, KLRD1, PRF1, and GZMB) associated genes, which allowed us 
to detect qualitative differences within individual T cells after vaccination with 
natural versus analog peptide. Our data revealed a vast co-expression of 
memory/homing- and effector-related genes in T cells induced by vaccination with 
natural peptide, similar to protective CMV-specific T cells, thus suggesting a higher 
degree of functional diversity which may be important for mounting efficient 
responses to pathogens or tumors. 
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MATERIALS AND METHODS 
Ethics statement 
The clinical studies were designed and conducted according to the relevant regulatory 
standards, and approved by (i) the ethical commission of the University of Lausanne 
(Lausanne, Switzerland), (ii) the Protocol Review Committee of the Ludwig Institute 
for Cancer Research (New York, USA), and (iii) Swissmedic (Bern, Switzerland). 
Patient recruitment, study procedures and blood withdrawal from patients and healthy 
donors were done upon written informed consent. 
 
Patients and vaccination protocol  
Four HLA-A*0201-positive patients with stage III/IV metastatic melanoma were 
included in a phase I clinical trial (LUD-00-018; www.clinicaltrials.gov, 
NCT00112229) of the Ludwig Institute for Cancer Research and the 
Multidisciplinary Oncology Center.21,25 Patients received monthly low-dose 
vaccinations injected subcutaneously with 100 µg of either the Melan-AMART-126-35 
unmodified natural peptide (EAAGIGILTV) or the Melan-AMART-126-35 analog A27L 
peptide (ELAGIGILTV), mixed with 0.5 mg CPG 7909 / PF-3512676 (provided by 
Pfizer/Coley Pharmaceutical Group; USA) and emulsified in Incomplete Freund’s 
Adjuvant (IFA) (Montanide ISA-51; Seppic, Puteaux, France).21  
 
Cell preparation, antibodies, and flow cytometry 
Peripheral blood mononuclear cells (PBMCs) were cryopreserved in RPMI 1640, 
40% FCS and 10% DMSO following a Ficoll-Paque gradient centrifugation. 
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Phycoerythrin (PE)-labeled HLA-A*0201/peptide multimers with A27L Melan-
AMART-126-35 (ELAGIGILTV), EBV BMLF1280-288 (GLCTLVAML), and CMV 
pp65495-503 (NLVPMVATV) were synthesized as described previously.26 CD8pos T 
cells were positively enriched using a MiniMACS device (Miltenyi Biotech, Bergish 
Gladbach, Germany), resulting in > 90% CD3posCD8pos cells. Bulk CD8-enriched T 
cells were stained using the following 5-color stain combination: (a) FITC-
conjugated anti-CD8 (BD Biosciences, Allschwil, Switzerland), (b) PE-conjugated 
anti-CD3 (BD Biosciences), (c) PE-Texas Red-conjugated anti-CD45RA (Beckman 
Coulter, Nyon, Switzerland), (d) APC-conjugated anti-CD28 (BD Biosciences), and 
(e) PE-Cy7-conjugated anti-CCR7 (BD Biosciences). Antigen-specific CD8-enriched 
T cells were first stained in PBS, 0.2% BSA, 50 µM EDTA with PE-HLA-A2/peptide 
multimers (1 µg/ml, 60 min, 4°C) followed by 20 min at 4°C with (a) FITC-
conjugated anti-CD28 (BD Biosciences), (b) PE-Texas Red-conjugated anti-
CD45RA (Beckman Coulter), (c) APC-Cy7-conjugated anti-CD8 (BD Biosciences), 
and (d) anti-CCR7 purified mAb (BD Biosciences) followed by APC-conjugated goat 
anti-rat IgG Ab (Caltag Laboratories, Burlingame, UK). Defined T cell sub-
populations were then sorted as five-, two- or single-cells on a FACSVantage or a 
FACSAria (BD Biosciences), and data were analyzed using FlowJoTM (TreeStar, 
Ashland, USA) software. For in vitro T cell cloning, 600 cells from defined 
subpopulations were sorted into tubes, and further processed as described thereafter. 
Manipulations were done at 4oC, avoiding gene expression alteration due to staining 
and sorting procedures. Immediate reanalysis of the FACS-sorted subpopulations 
revealed over 98% of purity.    
 
Direct ex vivo in-well cell lysis, and reverse transcription (RT) 
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Prior to FACS sorting, 10 ml of “Lysis buffer” was prepared using 9.22 ml RNAse 
free water molecular biology grade (AppliChem, Darmstadt, Germany), 400 µl of 0.1 
M DTT (AppliChem), 80 µl of 10 mg/ml tRNA (Roche Pharma, Reinach, 
Switzerland), 300 µl of 100% Triton X-100 (Sigma-Aldrich, Buchs, Switzerland) and 
stored in 1 ml aliquots at -20°C till further use. The “5X RT buffer” was prepared 
using 12.5 ml 1 M Tris-HCl (pH 8.3; AppliChem), 6.25 ml of 3 M KCl (AppliChem), 
750 µl of 1 M MgCl2 (AppliChem) in 30.5 ml RNAse free water for a final volume 
of 50 ml.  
For direct ex vivo lysis of FACS-sorted five-, two- or single-cells, 96-well V-bottom 
plates were prepared by adding 15 µl/well of a freshly prepared lysis/RT mix 
containing 6.3 µl of “Lysis buffer”, 3 µl of “5X RT buffer”, 1.5 µl of 0.1 M DTT, 
0.75 µl of 10 mM dNTPs (Invitrogen/ Life Technologies Corporation, Zug, 
Switzerland), 0.25 µl of 100 ng/µl oligo-(dT) (Metabion, Martinsried, Germany), 0.4 
µl of MMLV-RT enzyme (Invitrogen), 0.2 µl of RNAsin (Promega, Madison, WI), 
and 2.6 µl RNAse free water. Cells from (i) bulk CD3posCD8pos naive 
(CCR7posCD45RAposCD28pos) and EMRA (CCR7neg CD45RAposCD28neg) T cells, (ii) 
CD8pos tumor-specific effector-memory EM28pos (CCR7negCD45RAnegCD28pos) and 
EM28neg (CCR7negCD45RAneg CD28neg) T cells, and (iii) CD8pos virus-specific 
EM28pos (CCR7negCD45RAneg CD28pos) and EMRA (CCR7negCD45RAposCD28neg) T 
cells were directly sorted in 96-well V-bottom plates containing 15 µl of lysis/RT 
mix.  
Following ex vivo flow cytometry sorting, the plates were covered with a plastic 
adhesive cover and incubated at 37°C for 1 hour followed by a quick chill on ice. 
This allowed a direct ex vivo in-well cell lysis and reverse transcription to cDNA. The 
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plates were centrifuged at 1500 rpm for 1 min and transferred overnight to -80°C. 
The next day, the plates were thawed, and the content of each well was transferred to 
0.5 ml Eppendorf tubes. The tubes were placed at 90°C for 3 min to heat-inactivate 
the MMLV-RT enzyme, chilled on ice for 5 min and stored at -80°C until further use.  
 
Global cDNA amplification 
This procedure required a purification step (cDNA precipitation) followed by the 
addition of a homopolymer (dA) sequence to the 3’-OH end of the cDNA. Global 
cDNA amplification was then carried out using a single modified 61-mer oligo-(dT) 
primer as adapted from Brady and Iscove27 and Sauvageau et al.28 
cDNA precipitation: cDNA (from each tube stored at -80°C) was precipitated 
overnight at -80°C by adding 7.5 µl of 7.5 M NH4-acetate (AppliChem), 3 µl of 10 
mg/ml glycogen (Roche), and 45 µl of 100% ethanol. The tubes were then 
centrifuged at 4°C for 20 min (13000 rpm), and the supernatant was discarded 
carefully. cDNA pellets were washed with 150 µl of ice cold 70% ethanol and 
centrifuged at 4°C for 15 min (13000 rpm). After removing the supernatant, the 
pellets were air-dried for 45 to 60 min at room temperature. 
Homopolymeric 3’-oligo-(dA) tailing: The dried pellets were resuspended in 5 µl of 
tailing mix containing 0.25 µl of 10 mM dATP (Axonlab, Le Mont-sur-Lausanne, 
Switzerland), 0.08 µl of terminal deoxynucleotidyl transferase (TdT 30 U/ul; 
Promega), 1 µl of 5X tailing buffer (distributed with the TdT enzyme by the 
manufacturer), and 3.7 µl RNAse free water. The tubes were then incubated at 37°C 
in a water bath for 30 min followed by heat inactivation at 90°C for 3 min. After a 
quick chill on ice, tubes were centrifuged briefly at 13000 rpm.  
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Global cDNA amplification (cDNAplus): “5X PCR buffer” with a final 2 mM MgCl2 
concentration contained 250 mM of KCl (AppliChem), 50 mM of Tris-HCl (pH 8.8; 
AppliChem), 0.5 mg/ml BSA (bovine serum albumine; Roche) and 10 mM MgCl2. 
Aliquots of the “5x PCR buffer” were prepared and stored at -20°C. The PCR mix-A 
was prepared on ice and contained 8 µl of 5X PCR buffer, 1 µl of oligo-(dT) Iscove 
61-mer primer (HPLC purified, 1 µg/µl, 5’-CAT GTC GTC CAG GCC GCT CTG 
GGA CAA AAT ATG AAT TCT TTT TTT TTT TTT TTT TTT TTT T-3’; 
Metabion), 1 µl of 10 mM dNTP (Sigma), 2.5 µl of 10% Triton-X100 (Sigma) and 
22.5 µl RNAse free water. Into each tube containing the 3’ oligo-(dA)-tailed cDNA, 
35 µl of PCR mix-A was added followed by two drops of mineral oil (Eurobio, Les 
Ulis, France). Tubes were placed into a PCR machine (BioLabo, Maizy, France) and 
the cDNA was denatured by heating at 90°C for 3 min followed by an immediate 
addition of 10 µl of PCR mix-B containing 2 µl of 5X PCR buffer, 1 µl Taq 
polymerase (5 U/ul; Sigma) and 7 µl RNAse free water prior starting the PCR 
reaction. The PCR was carried out for first 5 cycles (50 s at 94°C; 2 min at 37°C; 9 
min at 72°C) followed by 35 cycles (50 s at 94°C; 90 s at 60°C; 8 min at 72°C) and a 
final extension for 8 min at 72°C. This cDNAplus was stably stored at -80°C for 
several months or years. All ex vivo five-, two-, and single-cell cDNA samples were 
processed with the same rigorous approach to allow direct comparison among 
individuals and subsets. 
 
Gene-specific PCR 
To avoid PCR contamination, the PCR mixes were prepared in a clean and different 
laboratory area than the ones used for single-cell cDNA preparation and global 
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amplification (cDNAplus). Gene signature of each individual cell was identified by 
gene-specific PCRs using 1 µl of amplified cDNAplus in 20 µl volumes of 4 µl of “5X 
PCR buffer” with a final 1.5 mM MgCl2 concentration, 0.4 µl of 10 mM dNTPs, 0.4 
µl each forward and reverse specific primers designed to amplify mRNA sequences 
of interest (100 ng/µl; Metabion), 0.1 µl of Taq polymerase JumpStart (5 U/µl, 
Sigma), and 13.7 µl of RNAse free water. The PCR amplification was carried out at 
94°C for 3 min followed by 38-40 cycles (30 s at 94°C; 45 s at 58°C or 60°C; 1 min 
at 72°C) followed by 1 cycle (10 min at 72°C). The PCR products were visualized 
after electrophoresis on a 1.5% agarose gel. Typically, we used H2O for the negative 
PCR control, while 1 x 103 PBMCs from a healthy individual were used as positive 
PCR control. 
For specific gene expression analysis, we carefully designed our specific primers in 
such a way that they are usually located within the first 1000 bp upstream of the 3’-
poly(dA) end of the mRNA sequence, and whenever possible inter-exonic, thus 
excluding genomic DNA amplification. We used the following primers: GAPDH: 5’-
GGACCTGACCTGCCGTCTAG-3’; rev-5’-CCACCACCCTGTTGCTGTAG-3’, β2 
microglobulin: 5’-CCAGCAGAGAATGGAAAGTC-3’; rev-5’-GATGCTGCTTA 
CATGTCTCG-3’, CCR7: 5’-CCAGGCCTTATCTCCAAGACC-3’; rev-5’-
GCATGTCATCCCCACTCTG-3’, CD27: 5’-ACGTGACAGAGTGCC TTTTCG-3’; 
rev-5’-TTTGCCCGTCTTGTAGCATG-3’, IL7R (IL-7Rα/CD127): 5’-
ATCTTGGCCTGTGTGTTATGG-3’; rev-5’-ATTCTTCTAGTTGCTGAGGAA 
ACG-3’; EOMES (eomesodermin): 5’-AGCAGGCTGTGAACATTGG-3’; rev-5’-
TTGACTCCTGGGCCTAGTATC-3’, CXCR3: 5’-GCACCATTGCTGCTCCTTAG-
3’; rev-5’-TACGCCATGCCTTGTACTCC-3’, CCR5: 5-TCAGCAGGAAGCAA 
CGAAGG-3’; rev-5’-TCTTTGACTTGGCCCAGAGG-3’, KLRD1 (CD94) (located 
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at -2611 bp): 5’-GTGGGAGAATGGCTCTGCAC-3’; rev-5’-TGAGCTGTTGCTTA 
CAGATATAACGA-3’, IFNG (IFN-γ): 5’-GCCAACCTAAGCAAGATCCCA-3’; 
rev-5’-GGAAGCACCAGGCATGAAATC-3’, PRF1 (Perforin): 5’-TTCACTGCC 
ACGGATGCCTAT-3’; rev-5’-GCGGAATTTTAGGTGGCCA-3’, GZMB 
(Granzyme B): 5’-GCAGGAAGATCGAAAGTGCGA-3’; rev-5’-GCATGCCAT 
TGTTTCGTCCAT-3’.  
 
Generation of T cell clones 
HLA-A2/multimerpos CD8pos T cell subsets (EM28pos, EM28neg, and EMRA) were 
sorted by flow cytometry,29,30 cloned by limiting dilution, and expanded in RPMI 
1640 medium supplemented with 8% human serum, 150 U/ml recombinant human 
IL-2 (rhIL-2; a gift from GlaxoSmithKline, Münchenbuchsee, Switzerland), 1 µg/ml 
phytohemagglutinin (PHA; Sodiag, Losone, Switzerland) and 1 × 106/ml irradiated 
allogeneic PBMC (3000 rad) as feeder cells. T cell clones were expanded by periodic 
(every 15 days) restimulation with PHA, irradiated feeder cells, and rhIL-2. Cells (1 x 
104) from T cell clones, were directly processed through direct cell lysis and cDNA 
synthesis as described above without undergoing the global cDNA amplification 
procedure.  
 
TCR Vβ chain repertoire and clonotype analysis 
TCR BV repertoire analysis or CDR3 spectratyping was performed as described 
previously.29,30 Briefly, pools of the equivalent of 50 cells were subjected to 
individual PCR in non-saturating conditions using a set of previously validated 
fluorescent-labeled forward primers specific for the 22 TCR BV subfamilies and one 
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unlabeled reverse primer specific for the constant region of the β chain of the TCR.31 
This analysis represented a screening step. Once positive TCR BV subfamilies were 
identified, the following step consisted in subjecting each individually generated 
single-cell cDNA sample, and in parallel in vitro generated T cell clone to TCR BV 
PCRs. Separation and detection of amplified fragments containing the entire CDR3 
segment was performed in the presence of fluorescent size markers on an ABI 
PRISM 310 Genetic Analyzer (AppliedBiosystems/Life Technologies Corporation, 
Zug, Switzerland) and data were analyzed with GeneScan 3.7.1 (AppliedBiosystems). 
In the last step, PCR products of interest were directly purified and sequenced with 
the reverse primer (Fasteris SA, Geneva, Switzerland). Clonotypic primers for several 
CDR3 sequences were validated and used in clonotypic PCR for determination of 
clonotype frequencies as previously reported.29,30 All direct ex vivo single-cell and in 
vitro T cell clone cDNA samples were processed with the same rigorous approach to 
allow direct comparison among individuals and subsets.  
 
Enzyme Linked Immunospot (Elispot) assay 
To evaluate the ex vivo functional potential of tumor-specific T cells from vaccinated 
melanoma patients, IFN-γ Elispot assays were performed as described.25 Briefly, 
plates were coated overnight with human IFN-γ-specific antibodies (Diaclone, 
Biotest, Rupperswil, Switzerland), and washed. In 3-6 replicates, 1.66 × 105 
PBMCs/well were stimulated with 10 µg/ml of the native Melan-AMART-126-35 peptide 
(EAAGIGILTV) for 16 hours at 37oC. Cells were removed, and plates developed 
with a second biotinylated antibody to human IFN-γ and streptavidin-alkaline 
phosphatase (Diaclone, Biotest). The spots were revealed with BCIP/NBT substrate 
and counted with an automatic reader (Bioreader 2000; BioSys GmbH, Karben, 
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Germany). The proportion of primed tumor-specific CD8pos T cells following 
multimer, CD8, CD45RA and CCR7 co-stainings was determined by flow cytometry 
on the same batch of cryopreserved cells. Elispot-forming T cells are expressed as 
percentage of non-naive (non-CD45RAposCCR7pos) multimerpos CD8pos T cells.   
 
Chromium release and target cell killing assays 
Tumor-specific T cell clones were generated in vitro from four patients with 
melanoma following analog/ELA (n = 2) or natural/EAA (n = 2) peptide vaccination. 
Lytic activity and antigen recognition was assessed functionally in 4-hour 51Cr-
release assays using T2 target cells (HLA-A*0201pos/TAPneg/neg) pulsed with serial 
dilutions of the native Melan-AMART-126-35 peptide (EAAGIGILTV). The percentage 
of specific lysis was calculated as 100 × (experimental − spontaneous release)/(total − 
spontaneous release). 
 
Statistical analyses 
For quantitative comparison, linear regression analysis with 95% confidence intervals 
or two-tailed unpaired t test were performed with Prism 5.0 (La Jolla, California, 
USA), while one-way ANOVA test was performed by SPSS statistical version 19 
(IBM, Chicago, USA). Co-expression pie charts were compared with each other 
using 10’000 permutations calculated with the Software SPICE 5.2 (NIH, Bethesda, 
USA).   
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RESULTS 
Global cDNA amplification and validation of single-cell gene expression analysis 
Following FACS-sorting of CD8pos T cell subsets of interest (bulk or antigen-specific 
cells), single cells were directly lysed in-well before reverse transcription of mRNA 
to cDNA, and subsequent global amplification of total cDNA (Fig. 1). The basic 
principle of this approach required that the target cellular cDNA be flanked by known 
sequences to which the amplification primers can anneal and initiate polymerization. 
As such, the reverse transcription was completed using an oligo-(dT) primer that 
annealed to the poly(A) tail present at the 3’ end of most mRNA molecules (Fig. 1A; 
step 2). Next, a homopolymer (dA) sequence was added to the 3’-OH end of the 
cDNA using terminal deoxynucleotidyl transferase (Fig. 1A; step 3). Global PCR 
amplification of the (dA)/(dT) flanked cDNAs was then carried out using a single 61-
mer modified oligo-(dT) primer, as previously described by Brady and Iscove.27 
Specifically, priming of the cDNA during global PCR amplification was initiated via 
annealing of the (dT) region of this modified oligo-(dT) primer to the poly(dA) 
regions present at the 3’ termini of the cDNA molecules (Fig. 1A; step 4). Since our 
approach uses oligo-(dT) based mRNA amplification, the only pre-requisite for the 
present technique is the careful design of primers such that they fall within the 1000 
bp from the 3’ end of mRNA. The efficiency of globally amplified cDNA from single 
CD8pos T cells, also termed cDNAplus (Fig. 1A; step 5), was then analyzed for the 
expression of housekeeping genes like glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) and beta-2-microglobulin (B2M) by semi-quantitative PCR. This 
represents a pre-screening step allowing selecting for positive GAPDH and/or B2M 
single-cell samples which will be further subjected to specific gene expression PCRs. 
The average efficiency of > 2400 single cells analyzed was close to 80% and 90% 
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using GAPDH and B2M, respectively (Fig. 1B), demonstrating robust reproducibility 
of our cDNAplus approach.  
 
Sensitivity and specificity of the single-cell cDNAplus approach  
Serial dilutions of single-cell cDNAplus from sorted bulk CD8pos T cells and from 
sorted naive and EMRA/effector CD8pos T cell subsets were compared to cDNAplus 
from five- and two-cell samples (Fig. 2A). Amplified poly-(dA) cDNAplus allowed 
the detection of robust PCR signals for GAPDH in bulk CD8pos T cells, as well as for 
the homing chemokine receptor CCR7 (CCR7) in naive cells and for granzyme B 
(GZMB) in EMRA cells, even at high dilutions (10-4). Our results show that the PCR 
sensitivity with cDNAplus obtained from single cells was comparable to PCR with 
cDNAplus isolated from five-cells and two-cells samples.  
We next determined the specificity of the single-cell approach by assessing the 
expression of a panel of genes known to be differentially expressed in the naive 
CD8pos T cell subset compared to the EMRA/effector differentiated subset (Fig. 2B). 
As expected, most of the naive T cell cDNAplus samples yielded detectable expression 
of CCR7, CD27 (a member of the TNF-receptor superfamily) and IL7R (the cytokine 
receptor IL-7Rα). In sharp contrast, these mRNA transcripts were rarely found in the 
EMRA/effector T cells, which instead contained significant levels of mRNA coding 
for effector mediators such as the natural killer cell-receptor CD94 (KLRD1), IFN-γ 
(IFNG), perforin (PRF1) or granzyme B (GZMB). Taken together, these data 
demonstrate the remarkable sensitivity and specificity of the single-cell cDNAplus 
approach, wherein CD8pos T cells can be individually sorted directly ex vivo 
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according to well-defined subpopulations and specific-gene expression profiles 
subsequently analyzed (Fig. 2). 
 
TCR β-chain repertoires and clonotype frequencies determined by the direct ex vivo 
single-cell approach strongly correlate with results obtained by in vitro T cell 
cloning  
Our single-cell gene expression analysis approach allows analyzing individual TCR-
BV-CDR3β sequence motifs. Therefore, we determined the TCR clonotype 
repertoires of tumor- and virus-specific CD8pos T cell subpopulations. Specifically, 
individual cells from tumor-specific CD8pos T lymphocytes from melanoma patients 
following vaccination with either natural/EAA or analog/ELA Melan-AMART-126-35 
peptide were FACS-sorted and characterized for their TCR clonotype repertoire. The 
same experimental procedure was performed on EBV- (Epstein-Barr-virus) and 
CMV- (Cytomegalovirus) specific single T cells from healthy donors.  
The TCR clonotype repertoire analysis of directly ex vivo sorted single tumor- and 
virus-specific T cells was first compared with that of single T cells generated by in 
vitro limiting dilution cultures, which has long been the method of choice for 
assessing TCR BV gene segment usage.19 Despite a large usage of the 22 different 
TCR BV families, in line with our previous reports,29,30 we observed highly similar 
proportions of TCR BV family usage (Fig. 3A) and of individual TCR clonotype 
signatures (Fig. 3B) with both the direct ex vivo single-cell and the in vitro T cell 
cloning approaches. In particular, the single-cell analysis confirmed that TCR β-chain 
repertoires were broader after vaccination with natural than analog peptide.29 
Moreover, the EBV-specific TCR repertoire showed a preferential usage of TCR 
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BV2 and BV4 gene segments with a wider variety of T cell clonotypes as compared 
to the restricted CMV-specific TCR β-chain repertoire.30 Remarkably, the relative 
proportions of dominant T cell clonotypes, and to a lesser extent of sub-dominant 
clonotypes (with frequencies < 20%), were found to be very similar using either of 
the two techniques, resulting in a high correlation coefficient (Fig. 3C). Collectively, 
our results based from the direct ex vivo single-cell cDNAplus-based analysis are in 
excellent agreement with those obtained with large numbers of in vitro generated T 
cell clones. 
 
Natural peptide vaccination induced tumor-specific CD8pos T cells with superior 
effector functions compared to vaccination with the analog peptide 
Vaccine-induced Melan-AMART-1-specific CD8pos T lymphocytes have been shown to 
exhibit an “effector-memory” (EM; CD45RAnegCCR7neg) phenotype32 and to include 
two distinct functional subsets distinguished by CD28 expression24,33; (i) CD28pos 
(defined thereafter as EM28pos or early-differentiated) T cells and (ii) CD28neg 
(EM28neg or late-differentiated) cells (Fig. 4A). In contrast, EBV- and CMV-specific 
CD8pos T cells are mostly composed of early- (EM28pos) and late-differentiated 
(EMRA; CD45RAposCCR7negCD28neg) subsets, but they vary in the proportions of 
these subsets.30 EM28neg and EMRA subsets can be both defined as late-differentiated 
“effector-like” T lymphocytes.34 Accumulation of CD28neg tumor-specific T cell 
subsets occurred following vaccination with the natural/EAA Melan-AMART-126-35 
peptide, comparable to that of protective T cell responses specific for CMV (Fig. 
4A). The proportion of “early-differentiated” CD28pos T cells was maintained after 
peptide vaccination and was very similar between tumor- and virus-specific T cell 
responses. 
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In line with our previous reports,21,24 vaccination with the natural/EAA peptide 
induced more robust T cell activation with increased proportions of IFN-γ producing 
T cells by Elispot assays as compared to the T cell responses following vaccination 
with the analog/ELA Melan-AMART-126-35 peptide (Fig. 4B). Moreover, natural/EAA 
peptide vaccine-induced T cell clones derived from EM28pos cells exhibited superior 
target cell killing responses, compared to T cell clones from the corresponding subset 
upon analog/ELA peptide vaccination (Fig. 4C). In contrast, most of tumor-specific T 
cell clones derived from the differentiated “effector-like” EM28neg subset showed 
similar efficient lysis capacity, irrespectively of the peptide used for vaccination. 
Extended co-expression of memory/homing- and effector-associated mRNA 
transcripts in single tumor-specific T cells induced by natural peptide vaccination 
The powerful single-cell based approach enabled the assessment of expression of 
memory- and effector-related gene patterns from individual tumor- and virus-specific 
CD8pos T cells directly ex vivo. We designed PCR primers for a panel of genes related 
to memory and homing (CD27, IL7R, EOMES, CXCR3 and CCR5) or effector 
(IFNG, KLRD1, PRF1, and GZMB) T cell properties.20,32,35-40 High expression of 
memory/homing-associated mRNA transcripts was observed in the early-
differentiated EM28pos tumor- and virus-specific subsets, while expression of 
effector-associated gene mediators was preferentially found in the late-differentiated 
EM28neg/EMRA T cells (Fig. 4D and 4E). Interestingly, EM28pos EBV-specific T 
cells had the highest expression of memory/homing-related genes (Fig. 4D), which 
contrasted to relatively low effector-gene expression (Fig. 4E), in agreement with our 
previous reports.24,30 T cell responses induced by the natural/EAA peptide vaccine 
triggered memory/homing-associated gene expression patterns that were in between 
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that of persistent EBV and analog/ELA peptide vaccine-induced T cells (Fig. 4D, left 
panel). Specifically, we observed significantly enhanced expression of CD27, CCR5 
and the transcription factor EOMES within those T cells, compared to tumor-specific 
T cells following analog peptide vaccination. Importantly, a large proportion of the 
natural peptide vaccine-induced T cells expressed as well IFNG, KLRD1 (CD94), 
PRF1 and GZMB mRNA transcripts (Fig. 4E), even in the less differentiated EM28pos 
T cell compartment where the difference to the analog peptide induced T cells was 
statistically significant (Fig. 4E, left panel).  
Subsequently we analyzed the gene expression polyfunctionality as well as the 
heterogeneity of co-expression patterns of either memory/homing- or effector-
associated genes along cell differentiation (Fig. 5). We found that vaccination with 
the analog/ELA peptide induced T cells with only limited co-expression, particularly 
for effector-associated genes in the early-differentiated EM28pos subset (Fig. 5A), and 
for memory/homing-associated genes in the late-differentiated EM28neg/EMRA 
subsets (Fig. 5B). These data are in sharp contrast to the single T cells induced by 
vaccination with the natural/EAA peptide, showing impressive gene expression 
polyfunctionality and co-expression variability of memory/homing- and of effector-
associated transcripts (up to 3/4 co-expressing genes). These co-expression patterns 
were preferentially found in the early-differentiated subset, and resembled those 
observed in protective CMV-specific T cells (Fig. 5A). These findings indicate a 
differential process of cell differentiation following natural versus analog peptide 
vaccination, and show that the peptide used for vaccination determines the functional 
properties of individual tumor-specific T cells. 
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Natural peptide vaccination induced highly diverse individual T cells co-expressing 
multiple different memory/homing and effector gene patterns directly ex vivo  
To assess the gene expression diversity among vaccine-induced T cells, we analyzed 
the distributions of tumor- and virus-specific T cells depending on their simultaneous 
co-expression of both memory/homing- and effector-associated gene transcripts. 
Single T cells with all possible combinations of gene expression were plotted on 
three-dimensional matrix (Fig. 6), according to expression of 0 to 5 memory/homing 
genes (IL7R, CD27, EOMES, CXCR3, and CCR5) versus 0 to 4 effector-genes 
(IFNG, KLRD1, PRF1 and GZMB). The data revealed an extraordinary diversity in 
terms of memory/homing and effector gene co-expression patterns by individual 
cells. Specifically, tumor-specific T cells induced by the natural/EAA peptide vaccine 
frequently co-expressed various combinations of multiple memory/homing- and 
multiple effector-associated mRNA transcripts (Fig. 6A, right panel). This was best 
illustrated for the single T cells issued from the early-differentiated EM28pos subset, 
co-expressing up to 5 memory/homing- and 4 effector-related genes.  
In contrast, analog/ELA peptide vaccine-induced T cells showed distinct 
memory/homing and effector-related gene co-expression patterns that were highly 
dependent on the differentiation stage (Fig. 6A, left panel), in agreement with the 
above-described results (Fig. 4 and Fig. 5). The early-differentiated EM28pos subset 
primarily expressed memory/homing-associated transcripts, while the late-
differentiated EM28neg cells mostly expressed effector-associated genes (up to 4 co-
expressing transcripts) with only rare memory/homing-gene co-expression (up to 1-2 
co-expressing transcripts). Finally, EBV- and CMV-specific T cells displayed 
memory/effector gene-co-expression patterns that placed them in between those 
observed for the natural and analog peptide vaccination induced T cells (Fig. 6B).   
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Heterogeneity and co-expression of memory/homing and effector gene transcripts by 
tumor- and virus-specific T cell clonotypes  
We recently reported a progressive restriction in the TCR BV/CDR3 diversity along 
cell differentiation (from EM28pos to EM28neg).24 T cell receptor (TCR) clonotype 
mapping revealed preferential selection and expansion of co-dominant T cell 
clonotypes, which made up between 50 to 60% of the differentiated “effector” T 
cells, but only 25% on average of the early-differentiated EM28pos cells, mostly 
composed of non-dominant clonotypes. A striking observation was that tumor-
reactive T cell responses were in several patients dominated by individual clones,33,41 
such as for example BV17.1 clonotype for patient LAU 618 or BV13.1 clonotype for 
patient LAU 1013 (Fig. 7). This process occurred irrespective of whether natural or 
analog peptide was used for vaccination, and resembled that observed in EBV and 
CMV specific T cells.30 
Here we extended these analyses by assessing the direct ex vivo co-expression 
patterns of memory/homing- and effector-associated genes within the dominant T cell 
clonotypes that were selected with advanced differentiation, i.e. clonotypes found in 
both EM28pos and EM28neg subsets, compared to those that were not (Fig. 7). The 
memory/homing and effector gene co-expression profiles of all dominant EM28pos T 
cell clonotypes (Fig. 7A) largely overlapped with those of the corresponding early-
differentiated EM28pos subset (Fig. 5A). For example, BV13.1 clonotype induced by 
the natural/EAA peptide vaccination (from patient LAU 1013) was highly 
polyfunctional, with > 3 co-expressing memory/homing and/or effector genes. In 
contrast, BV17.1, BV3.1 and BV13.2 clonotypes from patient LAU 618 vaccinated 
with the analog/ELA peptide were globally less polyfunctional (Fig. 7A). In the 
differentiated EM28neg subset, all selected clonotypes showed reduced 
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memory/homing-related gene co-expression, while maintaining or further acquiring 
effector-mediated gene co-expression (Fig. 7B).  
Importantly, the gene profiles of the EM28pos T cell clonotypes that were highly 
selected with differentiation were more polyfunctional (co-expressing ≥ 2 
memory/homing- or effector-associated genes) compared to those that were not 
selected or remained at low frequencies (Fig. 7A). Indeed, many of the unselected 
(e.g. BV3.1 and BV13.2 clonotypes from LAU 618) or the less frequently selected 
(e.g. BV7.3/BV14.1/BV13.3 clonotypes from LAU 1013) single T cells exhibited 
reduced co-expression of mRNAs coding for either memory/homing- or effector-
mediating molecules. Of note, dominant T cell clonotypes from EBV-specific T cell 
responses or from the two other vaccinated melanoma patients could not be included 
in this study, as we were unable to identify sufficient numbers of co-existing single T 
cell clonotypes shared between both EM28pos and EM28neg/EMRA subsets. 
Collectively, our data show that the single-cell approach represents a powerful tool to 
characterize fine differences within the TCR-based clonotype selection and 
composition of tumor-reactive CD8pos T cells along T cell differentiation (early- 
versus late-differentiation). It further suggests that the selection of T cell clonotypes 
with cell differentiation may not strictly depend on TCR-related parameters (e.g. 
TCR-pMHC affinity/avidity), but may as well involve the co-expression within the 
same cell of particular memory/homing- and effector-mediated gene patterns.  
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DISCUSSION 
The results presented in this study offer novel insights on cellular heterogeneity and 
polyfunctionality within tumor- and virus-specific CD8pos T cell sub-populations. It is 
becoming increasingly clear that analyses based on cell averages within a given 
population may be misleading. Even within carefully sorted cellular populations, 
there remains significant cellular diversity. It is possible to discriminate immune cell 
heterogeneity at three different levels. First, T cells may be identified at the sub-
population level of relatively diverse memory- and effector-related T cells based on 
their expression of costimulatory molecules CD27 and CD28 and other surface 
markers.36 At a second level, it is also possible to demonstrate immune cell 
heterogeneity based on the polyfunctionality of T cell sub-populations. Finally, a 
third level of immune cell heterogeneity is now perceptible at the basic biological 
unit: the individual cell. The notion of varying degrees of polyfunctionality of 
individual cells reveals the diversity of seemingly well-defined sub-populations or 
subsets, demonstrating the heterogeneity of antigen-specific T cell responding to 
antigenic challenges. 
The fast advancing field of multiparameter flow cytometry combined with novel 
strategies for gene expression profiling of antigen-specific T cells of particular 
phenotypes have opened new opportunities for performing detailed analyses at the 
individual cell level. For this purpose, we previously developed a strategy consisting 
of cell lysis and cDNA synthesis in a single-step procedure, followed by a modified 
PCR protocol that relies on the detection of specific cDNAs after global amplification 
of expressed mRNAs22,23 (Fig. 1). This method yielded sufficient cDNA from as few 
as five cells, which allowed us to follow tumor-specific T cells before and after 
therapeutic peptide vaccination,33,41 as well as EBV- and CMV-specific T cells from 
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healthy individuals over time.30 Recently, we have optimized the above-described 
strategy of global cDNA amplification at the single-cell level for direct ex vivo 
monitoring of gene expression profiles24 (Fig. 2 and Fig. 4). Other methods have been 
documented to quantify the gene expression profile of a single-cell, all with their own 
uses, advantages and drawbacks.42-46 Without contesting the validity and specificity 
of these techniques, we believe that our approach has the added advantages of 
practicality, low-cost and adaptability. By utilizing standard biological techniques 
(reverse transcription and semi-quantitative PCR), this single-cell method is 
affordable, as it does not require the engineering of novel microfluidic platforms14 or 
the assistance of robotic technologies, except for an efficient sorting facility. 
Nonetheless the implementation of automated steps is warranted to minimize sample 
manipulation, which may lead to contamination and loss of material. 
Furthermore, our method does not require pre-customization of genes for selective 
amplification and therefore is completely flexible regarding the genes analyzed. Each 
PCR needs only small volumes (0.5 to 1 µl) of the total cDNAplus sample, the 
remainder can thus safely be stored at -80˚C for any future analysis. By combining 
single-cell isolation with the characterization of defined TCR BV-CDR3 sequences, 
the TCR repertoire diversity and clonal composition of well-defined antigen-specific 
T cell subpopulations can also be characterized, and are in excellent agreement with 
the data obtained with large numbers of in vitro generated T cell clones (Fig. 3). In 
the present study, we examined the expression of cell surface markers/receptors and 
cytoplasmic proteins known to be associated with either effector or memory/homing 
functions. IFNG, KLRD1, GZMB and PRF1 all encode for proteins well characterized 
to be expressed by effector CD8pos T cells.32,40 Conversely, CD2738 and IL7R37 are 
used as markers of the memory phenotype. CCR5 and CXCR3 are involved in 
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cellular migration and homing into inflamed tissue and are upregulated on memory 
cells.20,35,47,48 Finally, although EOMES can drive the differentiation of effector 
CD8pos T cells in partnership with T-bet,39 it is also involved in central-memory T 
cell differentiation and longevity.49 Future direction involves the fine characterization 
at the single-cell level of transcriptional factors and their co-expression patterns 
involved in the regulation and differentiation of early- and late-differentiated antigen-
specific CD8pos T cells. 
Single-cell analyses have been documented in various fields of research, but few 
studies have focused on the heterogeneity of T cell responses. Recent data suggest 
that the T cell heterogeneity begins at the level of cell division. By monitoring the 
cellular localization of key immune cell fate mediators, Chang et al. demonstrated 
that, following initial antigen encounter, naive T cells undergo stem cell-like 
asymmetrical cell division yielding daughter cells with either memory or effector 
properties.50 In a different in vivo model, the microinjection of a single naive T cell 
was also shown to repopulate a host with a progeny of differentiated effector and 
memory cells.51 These studies speak of the diversification potential of naive T cells, 
but yet do not address the polyfunctionality of individual cells. Single-cell based gene 
expression approaches were particularly successful in gaining insights in T cell 
heterogeneity and intrinsic polyfunctionality following primary antigenic stimulation 
or therapeutic vaccination.20,52 Our data are in line with these observations and further 
illustrate the increased level of diversity in terms of simultaneous co-expression of 
memory/homing- and effector-related genes, which we observed for both tumor- and 
virus-specific T cells, within defined subsets (EM28pos and EM28neg/EMRA) and 
specific TCR clonotypes (Fig. 5, Fig. 6 and Fig. 7). 
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Polyfunctional antigen-specific CD8pos T cells have been commonly observed in 
response to viral diseases, both for acute (e.g. influenza) as well as for persistent but 
efficiently controlled (e.g. CMV and EBV) infections. Similarly, a higher degree of 
polyfunctionality was also described within a small group of HIV-infected 
individuals named long-term non-progressors compared to those with progressing 
HIV disease.53,54 It seems likely that protective T cell responses against viral 
infections or malignant diseases rely on both phenotypic and functional heterogeneity 
with a greater than ever polyfunctionality. Along these lines, Newell and coworkers55 
have very recently described a large degree of functional diversity even among 
CD8pos T cells with the same specificity, thus allowing a remarkable degree of 
flexibility in responding to pathogens. Such extreme functional diversity may thus 
represent the successful step for tumor eradication and/or long-term survival in 
chronic diseases.56 
Peptide-based cancer vaccines have often been performed with analog peptide 
antigens designed for enhanced MHC class I binding. It is important to elucidate how 
these modifications may affect the generation of vaccine-specific T cell clonotype 
repertoires and tumor recognition efficiency by those T cells. We previously reported 
that compared with vaccination with the analog/ELA Melan-AMART-126-35 peptide,57 
natural/EAA peptide vaccination generates T cells with enhanced activation and 
effector functions.21 These observed differences could not be explained by 
structurally distinct TCRs, since vaccination with natural and analog peptide induced 
TCR repertoires with structurally conserved features of TCRαβ chains.29 However, 
when Cole and colleagues58 evaluated the intra-individual clonotypic responses to 
both natural and analog peptide, based on samples derived from the same naive T cell 
pool, they could show that the analog peptide primed T cells with largely different 
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TCRs compared with those primed with the natural antigen. More recently, we 
demonstrated that the observed superior tumor activity of the natural peptide induced 
T cells resulted from effector functions developing properly in nearly all dominant 
and low/non dominant tumor-specific T cell clonotypes, in contrast to T cells 
generated following natural Melan-AMART-126-35 peptide vaccination.24 Here, we 
strengthen these findings by uncovering a previously unknown level of gene 
expression diversity among natural peptide induced T cells, with the simultaneous co-
expression of memory/homing- and effector-related genes by the same cell. Our 
results further suggest that the natural peptide promotes a broader diversification of 
tumor-specific T cells, which may favor their activation and effector potential. 
Strikingly, memory/effector gene co-expression reflected a polyfunctionality that was 
also observed at the clonotypic level (Fig. 7, data not shown), which may be 
important for mounting potent immune responses against tumors and pathogens. 
Overall these data and those by others58-60 show that a single amino acid substitution 
within a peptide used for vaccination can have significant consequences on the 
quality of the T cell response. Further work is needed to elucidate the mechanisms 
involved in the qualitative superior T cell response induced by natural peptide 
vaccination. Nevertheless, direct ex vivo high-resolution molecular characterization 
of individual T cells as shown here provides enhanced insights in the processes 
shaping the functional properties of tumor-specific T cells.  
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FIGURE LEGENDS 
Figure 1. (A) Basic steps involved for global amplification of cDNA from FACS-
sorted individual CD8pos T cells directly ex vivo. (B) Efficiency of single-cell 
cDNAplus as a measure of positive PCR signals for the house-keeping genes GAPDH 
(33 independent experiments including a total of 1709 tested single-cell samples) 
and/or B2M (18 independent experiments including a total of 768 tested single-cell 
samples). Of note, comparable cDNAplus efficiencies were found within the same 
experiment and among different antigen-specific CD8pos T cell subsets (e.g. EM28pos 
versus EM28neg versus EMRA), data not shown.    
 
Figure 2. Sensitivity and specificity of the single-cell cDNAplus approach. (A) Serial 
dilutions of cDNAplus from 5, 2, and 1 cell(s) sorted from bulk CD8pos, naive and 
EMRA CD8pos T cell subsets were tested for GAPDH, CCR7 and GZMB (Granzyme 
B) gene expression, respectively. The starting cDNAplus (isolated from 5, 2, or 1 cell) 
was prepared using 10-fold serial dilutions as indicated (Log10 of the reciprocal of the 
dilution value). Top panel shows a representative example of gene expression 
detection along serial dilutions. Bottom panel represents the exact number of positive 
PCR signals within the tested samples (n = 4) for each cDNAplus dilution. (B) Gene 
expression analysis was performed on single-cells sorted from naive (n = 29) or 
EMRA (n = 30) CD8pos T cell subsets. Data from 10 independent single-cell aliquots 
are depicted. The cumulative gene expression for all tested naive and EMRA single T 
cells is shown in the right panel.  
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Figure 3. Comparison of the proportion of TCR Vβ-chain usage (A) and clonotype 
diversity (B) between the direct ex vivo single-cell and the in vitro limiting dilution 
approach. (A) TCR BV family usage was determined on individual tumor-specific 
CD8pos T cells isolated from four patients vaccinated with the natural/EAA or 
analog/ELA peptide, and from EBV- and CMV-specific CD8pos T cells from healthy 
donors BCL6 and BCL8. Data are depicted as cumulative frequencies of TCR BV 
family usage of in vitro T cell clones versus direct ex vivo single T cells. (B) Relative 
frequencies of T cell clonotypes issued either from the ex vivo single-cell or the in 
vitro limiting dilution approach. Each symbol represents the proportion of a given 
clonotype from late-differentiated EM28neg (ELA and EAA) or EMRA (EBV and 
CMV) T cell subset. ELA, analog peptide vaccination; EAA, natural peptide 
vaccination. Of note, clonotypes bearing the TCR BV14 gene usage were often under 
represented by the ex vivo single-cell approach. (C) Positive correlation of clonotype 
frequencies obtained between direct ex vivo single-cell cDNAplus and in vitro single-
cell cloning (by linear regression analysis with 95% confidence intervals). The inset 
shows the correlation between sub-dominant clonotype frequencies (≤ 20% of 
prevalence). (A-C) TCR BV usage and clonotype repertoire analysis was performed 
as detailed in the Materials and Methods section. In vitro: data from single T cell 
clones generated by in vitro limiting dilutions (n = 1505). Ex vivo: data from FACS-
sorted single T cells and directly processed by cDNAplus gene expression 
amplification (n = 586). The TCR Vβ-chain nomenclature proposed by Arden et al. 
was used.61  
 
Figure 4. Functional competence and gene expression analysis of tumor-specific T 
cells following natural/EAA and analog/ELA peptide vaccination. (A) Ex vivo 
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analysis of circulating tumor-specific T cells in patients vaccinated with the analog (n 
= 10) or natural (n = 5) peptide, and virus-specific T cells from healthy donors (n = 
8). Data are expressed as percentage of CD28pos and CD28neg cells in multimerpos 
CD8pos T cells. (B) Ex vivo IFN-γ production by Melan-A-specific T cells following 
analog (n = 15) or natural (n = 9) peptide vaccination using Elispot assays. PBMCs 
were stimulated with the natural peptide (10 µg/ml) for 16 hours and data were 
calculated as percentage of primed multimerpos CD8pos T cells. *** P < 0.001 (two-
tailed unpaired t test). (C) Tumor cell killing was assessed by using T2 target cells 
(A2pos/TAPneg/neg) pulsed with graded concentration of the natural Melan-A peptide. 
Melan-A-specific T cell clones (n = 265) were generated in vitro following sorting of 
multimerpos EM28pos or EM28neg T cell subsets from melanoma patients who had 
been vaccinated with analog/ELA (n = 2) or natural/EAA (n = 2) peptide. Complete 
set of data representing maximal lysis. *** P < 0.001; ns, not significant (two-tailed 
unpaired t test). (D and E) Direct ex vivo cumulative expression of memory/homing 
and effector genes. Single tumor- and virus-specific EM28pos and EM28neg/EMRA T 
cells were sorted directly ex vivo from four patients vaccinated either with the 
analog/ELA (n = 2) or the natural/EAA (n = 2) peptide, as well as from two healthy 
donors with EBV- and CMV-specific T cell responses, and processed for cDNAplus 
amplification as described in Materials and Methods. Expression of (D) 
memory/homing-associated genes (CD27, IL7R, EOMES, CXCR3 and CCR5) and (E) 
effector-associated genes (IFNG, KLRD1, PRF1, and GZMB) was determined for 
each individual cDNAplus cell. EM28pos (n = 398) and EM28neg/EMRA (n = 412) 
tested single-cell samples. *** 0.0001 < P < 0.001; ** 0.001 < P < 0.01; * 0.01 < P < 
0.1; ns, not significant (by one-way ANOVA test).     
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Figure 5. Heterogeneity and co-expression of memory/homing and effector genes by 
tumor- and virus-specific T cells. Polyfunctional gene expression profile was 
determined as a measure of co-expression of the five memory/homing-associated 
gene transcripts (CD27, IL7R, EOMES, CXCR3 and CCR5) and the four effector-
associated gene transcripts (IFNG, KLRD1, PRF1, and GZMB) within early-
differentiated EM28pos (A) and late-differentiated EM28neg/EMRA (B) subsets. 
Colors of the pie arcs depict the co-expression of individual memory/homing or 
effector genes, while the color in the pie depicts the number of co-expressed 
memory/homing- or effector-associated genes, as determined by SPICE 5.2. 
Increased polyfunctional gene co-expression (from 0 up to 4 or 5) is shown as 
progressive color gradients. (A) EM28pos (n = 398) and (B) EM28neg/EMRA (n = 
412) tested single-cell samples. ELA, analog peptide vaccination; EAA, natural 
peptide vaccination. P-values of the permutation test are shown in the figure below to 
the corresponding pies.    
 
Figure 6. Direct ex vivo distribution of individual T cells according to combined 
simultaneous co-expression of memory/homing- and effector-associated gene 
transcripts. Memory/homing and effector- gene co-expression frequencies were 
determined for each single-cell (n = 810) and in all possible combinations using a 
three-dimensional matrix. X-axis, 0 to 5 memory/homing gene co-expression (M0 to 
M5 shown as progressive blue gradients; among IL7R, CD27, EOMES, CXCR3, and 
CCR5) versus z-axis, 0 to 4 effector gene co-expression (E0 to E4 shown as 
progressive red gradients; among IFNG, KLRD1, PRF1 and GZMB) versus single-
cell frequency (y-axis). Distribution of memory/homing and effector gene co-
expression patterns from (A) single EM28pos and EM28neg T cells sorted after analog 
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(n = 2) or natural (n = 2) peptide vaccination (four patients), and (B) from single 
EM28pos and EMRA T cells sorted from EBV- and CMV-specific T cells (from 
healthy donors BCL6 and BCL8).  
 
Figure 7. Heterogeneity and co-expression of memory/homing and effector gene 
patterns within dominant T cell clonotypes. Clonotypes were defined as dominant, 
when their relative frequencies within antigen-specific T cell subsets were found > 
10%.24 Analysis was performed on dominant T cell clonotypes that were shared 
between EM28pos and EM28neg/EMRA T cell subsets (selected with differentiation), 
as well as on dominant clonotypes that were exclusively found within the early-
differentiated EM28pos subset (not selected with differentiation). The proportion 
within EM28pos and EM28neg/EMRA T cell subsets is depicted for each T cell 
clonotype. Gene co-expression patterns were determined on the five 
memory/homing- (CD27, IL7R, EOMES, CXCR3 and CCR5) and the four effector- 
(IFNG, KLRD1, PRF1, and GZMB) associated gene transcripts within (A) early-
differentiated EM28pos and (B) late-differentiated EM28neg/EMRA subsets using 
SPICE 5.2. Colors of the pie arcs depict the direct ex vivo co-expression of individual 
memory/homing or effector genes, while the color in the pie depicts the number of 
co-expressed memory/homing- or effector-associated genes. Increased polyfunctional 
gene co-expression (from 0 up to 4 or 5) is shown as progressive color gradients. (A, 
B) ELA; analog peptide vaccination. EAA; natural peptide vaccination, n.a; not 
applicable. EM28pos (n = 143) and EM28neg/EMRA (n = 112) tested single-cell 
samples. 
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